Associated Papers
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic Resistance.
Mcdaid H et al.
Biorxiv : the Preprint Server for Biology, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Abdayem P et al.
Drugs, 2026
Targeting the Uncommon: A Case Report of Osimertinib Response in Advanced NSCLC Patient with Dual EGFR (E701fs and L702fs) Frameshift Deletions.
Wong AKQ et al.
Current Oncology (toronto, Ont.), 2026
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
van der Wel JWT et al.
Lung Cancer (amsterdam, Netherlands), 2025
Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
Lin F et al.
Genes, Chromosomes & Cancer, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Predicting Resistance to Small Molecule Kinase Inhibitors.
Nagarajan A et al.
Journal of Chemical Information and Modeling, 2025
Acquired multiple EGFR mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review.
Yang F et al.
Oncology Letters, 2025
A rare epidermal growth factor receptor T790M/cis-C797S/L718Q compound mutation in a lung adenocarcinoma patient who did not derive any benefit from combination therapy with afatinib and bevacizumab.
Meng X et al.
Sage Open Medical Case Reports, 2025
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
van der Wel JWT et al.
Neuro-oncology, 2024
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors.
Hickman RA et al.
Acta Neuropathologica Communications, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review.
Sun K et al.
Frontiers in Oncology, 2024
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Cho BC et al.
Nature Medicine, 2023
The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib.
Yang LL et al.
Translational Cancer Research, 2023
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
Lim SM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations.
He Q et al.
Cytokine & Growth Factor Reviews, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Guerin N et al.
Cell Systems, 2022
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Yap TA et al.
Jama Network Open, 2022
Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study.
Li HS et al.
Journal of Thoracic Disease, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T et al.
Cancer Science, 2022
Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.
Yin Y et al.
Jco Precision Oncology, 2022
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.
Wang H et al.
Frontiers in Oncology, 2022
Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N et al.
Experimental Cell Research, 2021
Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.
Di Noia V et al.
Esmo Open, 2021
PhosphoFlowSeq - A High-throughput Kinase Activity Assay for Screening Drug Resistance Mutations in EGFR.
Wagner A et al.
Journal of Molecular Biology, 2021
Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z et al.
Cell Death & Disease, 2021
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M et al.
Nature Communications, 2021
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective.
Zhu J et al.
Pharmaceutics, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry.
Scalvini L et al.
Biochemical Pharmacology, 2021